LEUKOTRIENE RECEPTORS STATE IN CHILDREN WITH BRONCHIAL ASTHMA

Barno T.  Khalmatova,

doi:10.61841/kzgv9x43

Authors

Barno T. Khalmatova, Barno T. Khalmatova-Head of the Department of Children’s diseases of the Tashkent Medical Academy Author

DOI:

https://doi.org/10.61841/kzgv9x43

Keywords:

Bronchial asthma,, children,, cysteinyl leukotrienes, clinic,, anti-leukotriene medications

Abstract

The aim of the workis to study the level of leukotrienes C4D4E4 in children with bronchial asthma and evaluate the effectiveness of the therapy. Materials and methods. The present research work was performed at the Department of Allergology of the Tashkent Medical Academy Clinic. In total 92 children with bronchial asthma underwent examination during the disease exacerbation. The control group included 23 rather healthy children of the same age. The diagnosis of bronchial asthma is established in accordance with the International Consensus on Diagnosis and Therapy of BA. Results and discussion. According to the aim of our work, we researched the level of leukotrienes С4D4Е4 in urine of 92 children with BA. Among them, there were 62 children with Step 1of BA (67.4%), and 30 children with Step 2 (32.6%). Comparative analysis of the initial data revealed a significant increase of LT release in 72 (78.3%) patients with cough form of BA. In 20 patients with Step 1 of BA, LT values were at the upper limit of the norm (1, 0 ± 0.01). 15 children with Step 2of BA showed an increase in the level of LT more than 5 times in comparison with the admissible norm (p < 0.05).Conclusion. The significant role of LT in the formation of allergic inflammation of the respiratory tractat BA in children has been confirmed. The prescription of cis-ALT (montelukast) is justified both as a monotherapy for mild persistent BA and in combination with IGCS in patients with moderate BA.

Downloads

Download data is not yet available.

References

[1] I.V. Vasilevskij, E.N, Skep'jan. Montelukast application experience in the treatment of bronchial asthma in children//Pediatric pharmacology. – 2017. – Т. 4. - №12. – p.15-21.

[2] L.R. Vyhristenko. Therapy with leukotriene receptor antagonists given phenotypic features of bronchial asthma//INTERNATIONAL REVIEWS: clinical practice and health №3 2016p. 20-37.

[3] M.H. Mirrahimova. BRONCHIAL ASTHMA IN CHILDREN: A MODERN VIEW OF THE PROBLEM

//Central Asian Journal of Medicine. – 2019. – Т. 2019. – №. 1. – p. 74-80.

[4] S.N. Nedel'skaja, O.P. Pahol'chuk, E.B. Raskina. The role of leukotriene receptor antagonists in the treatment of bronchial asthma in children // Asthmaand Allergy. – 2011. - № 1. – p.59-61.

[5] A.M. Fal, A. Kopeć. Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment// Pneumonologiaialergologiapolska. – 2010. - № 78(1). – р. 68-73.

[6] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (GINA). - National Institutes of Health; National Heart, Lung, and Blood Institute [accessed June 8, 2015; updated 2018].

[7] C.E. Grattan. Aspirin sensitivity and urticaria// Clinical and experimental dermatology. – 2003. - № 28(2). – p. 123-127.

[8] G. Gex, M. Nendaz, J.P. Janssens. Leukotriene-modifiers in asthma treatment// Revue médicalesuisse. – 2006. -

№ 2(77). – р. 1997-2006.

[9] M.L. Kowalski. Aspirin sensitive rhinosinusitis and asthma// Allergy proceedings: the official journal of regional and state allergy societies. – 1995. - № 16(2). – р. 77-80.

[10] L.Mastalerz, M. Setkowicz, M. Sanak, et al. Hypersensitivity to aspirin: common eicosanoid alteration in urticaria end asthma// The Journal of allergy and clinical immunology. – 2004. - № 113(4), p. 771-775.

[11] C. Micheletto, S. Tognella, M. Visconti, et al. Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics// Respiratory medicine. – 2006. - №

100(12). – р. 2144-2150.

[12] P.M. O’Byrne, G.M. Gauvreau, D.M. Murphy. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma// J Allergy Clin Immunol/ - 2009. - № 110(3). - р. 397-403.

[13] G. Riccioni, R. Della Vecchia, V. Menna, et al. Antileukotrienes in the therapy of bronchial asthma// Recentiprogressi in medicina. – 2003. - № 94(11). – р. 509-515.

[14] G.R. Tintinger, C. Feldman, A.J. Theron, et al. Montelukast: more than a cysteinyl leukotriene receptor antagonist?// TheScientificWorldJournal [electronic resource]. – 2010. - № 10. – р. 2403-2413.

[15] S.E. Wenzel. The role of leukotrienes in asthma// Prostaglandins, leukotrienes, and essential fatty acids. – 2003. -

№ 69(2-3). – р. 145-155.

[16] H.J. Zeitz. Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter's syndrome// Clinics in chest medicine. – 1988. - № 9(4). – р. 567-576.

[17] Z. Erbagci. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study// J Allergy Clin Immunol. - 2002. - № 124(3). – р.484- 492.

[18] Tabatabaei, S.M., Malekmakan, L., Izadpanahi, N., Mansourian, A.

[19] Comparative study of duration of spinal anesthesia with marcaine and lidocaine plus fentanyl between opium abuse and non-nonuse patients(2018) International Journal of Pharmaceutical Research, 10 (1), pp. 341-345.

[20] Gharagozlou,H.,&Mahboobi,M. (2015). Assessment of need for attention to the issue of security in usage of Information Technology (Including Case study). International Academic Journal of Science and Engineering, 2(12), 31-45.

[21] Ghaforiyan,H.,&Emadi,M. (2016). Human face recognition under pose variation with fusion geometric methods. International Academic Journal of Science and Engineering, 3(1), 1-9.

[22] Wang, E., Chao, W., Qin, S., Wan, Y. The mere exposure effect of different parts of speech: The evidence from ERP (2019) NeuroQuantology, 17 (2), pp. 79-90.

[23] Hao, Y., Dai, J. Propagation of action potential mediated by microtubules may involve in the neural quantum mechanism (2019) NeuroQuantology, 17 (2), pp. 72-78.